All Hong Kong stocks quotes are at least 15 minutes delayed.
06938
RIBOLIFE-B
HKD
68.550-0.750
(-1.08%)
1D
AI Analysis
High
70.350
Open
69.300
VWAP
67.05
Vol
388.00K
Mkt Cap
--
Low
64.500
Amount
26.02M
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.
Show More
News
Money Flow
Over the past 16 trading days, overall net money flow is 14.62M, with retail investors contributing 2.04M and major investors adding 10.86M.
Net Buy $ Volume
Net Sell $ Volume

No data
Valuation Metrics
Forward PE

N/A
5Y Average PE
Current PE
-
Overvalued PE
Undervalued PE
Forward EV/EBITDA

N/A
5Y Average EV/EBITDA
Current EV/EBITDA
-
Overvalued EV/EBITDA
Undervalued EV/EBITDA
Forward PS

N/A
5Y Average PS
Current PS
-
Overvalued PS
Undervalued PS
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly

No data

No data
People Also Watch


